OTCPK:OCPN.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. More Details


Snowflake Analysis

Solid track record with adequate balance sheet.


Similar Companies

Share Price & News

How has Olympus's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OCPN.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

OCPN.F

-2.5%

US Medical Equipment

-3.1%

US Market


1 Year Return

n/a

OCPN.F

14.6%

US Medical Equipment

12.7%

US Market

Return vs Industry: Insufficient data to determine how OCPN.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how OCPN.F performed against the US Market.


Shareholder returns

OCPN.FIndustryMarket
7 Day0%-2.5%-3.1%
30 Day0%-0.06%-2.9%
90 Day3.8%13.9%8.2%
1 Yearn/a15.6%14.6%15.3%12.7%
3 Year-46.8%-46.8%71.4%67.0%37.8%28.5%
5 Year-52.2%-52.2%149.1%130.4%90.9%69.4%

Price Volatility Vs. Market

How volatile is Olympus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Olympus undervalued compared to its fair value and its price relative to the market?

68.08x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: OCPN.F ($18.5) is trading above our estimate of fair value ($9.55)

Significantly Below Fair Value: OCPN.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: OCPN.F is poor value based on its PE Ratio (68.1x) compared to the US Medical Equipment industry average (48.3x).

PE vs Market: OCPN.F is poor value based on its PE Ratio (68.1x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: OCPN.F is poor value based on its PEG Ratio (2.7x)


Price to Book Ratio

PB vs Industry: OCPN.F is overvalued based on its PB Ratio (7.6x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Olympus forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

24.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OCPN.F's forecast earnings growth (24.8% per year) is above the savings rate (2.2%).

Earnings vs Market: OCPN.F's earnings (24.8% per year) are forecast to grow faster than the US market (23.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: OCPN.F's revenue (6.9% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: OCPN.F's revenue (6.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OCPN.F's Return on Equity is forecast to be low in 3 years time (19.5%).


Next Steps

Past Performance

How has Olympus performed over the past 5 years?

4.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OCPN.F has high quality earnings.

Growing Profit Margin: OCPN.F's current net profit margins (5.3%) are higher than last year (4.2%).


Past Earnings Growth Analysis

Earnings Trend: OCPN.F has become profitable over the past 5 years, growing earnings by 4.7% per year.

Accelerating Growth: OCPN.F's earnings growth over the past year (19.8%) exceeds its 5-year average (4.7% per year).

Earnings vs Industry: OCPN.F earnings growth over the past year (19.8%) exceeded the Medical Equipment industry -0.2%.


Return on Equity

High ROE: OCPN.F's Return on Equity (11.1%) is considered low.


Next Steps

Financial Health

How is Olympus's financial position?


Financial Position Analysis

Short Term Liabilities: OCPN.F's short term assets (¥604.4B) exceed its short term liabilities (¥340.3B).

Long Term Liabilities: OCPN.F's short term assets (¥604.4B) exceed its long term liabilities (¥396.8B).


Debt to Equity History and Analysis

Debt Level: OCPN.F's debt to equity ratio (106.9%) is considered high.

Reducing Debt: OCPN.F's debt to equity ratio has increased from 90.8% to 106.9% over the past 5 years.

Debt Coverage: OCPN.F's debt is well covered by operating cash flow (29.3%).

Interest Coverage: OCPN.F's interest payments on its debt are well covered by EBIT (43.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Olympus's current dividend yield, its reliability and sustainability?

0.47%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: OCPN.F's dividend (0.47%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.71%).

High Dividend: OCPN.F's dividend (0.47%) is low compared to the top 25% of dividend payers in the US market (4.88%).


Stability and Growth of Payments

Stable Dividend: OCPN.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: OCPN.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: OCPN.F is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OCPN.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Yasuo Takeuchi (63 yo)

1.42yrs

Tenure

Mr. Yasuo Takeuchi has been Chief Executive Officer and President of Olympus Corporation since April 1, 2019 and has been its Representative Executive Officer since 2019. He served as Chief Financial Offic ...


Leadership Team

NamePositionTenureCompensationOwnership
Hiroyuki Tsuji
Directorno dataJP¥119.16mno data
Yasuo Takeuchi
President1.42yrsno data0.0053%
¥ 1.4m
Chikashi Takeda
Executive Officer & CFO0.42yrno datano data
Nacho Abia
COO & Executive Officer0.42yrno datano data
Akihiro Taguchi
CTO & Executive Officer0.42yrno data0.0034%
¥ 883.6k
Stefan Kaufmann
Chief Administrative Officer1.25yrsno data0.000040%
¥ 10.4k
Donna Miller
Head of HQ Legal and Global General Counsel4.42yrsno datano data
Caroline H. West
Chief Compliance Officer4.42yrsno datano data
Mark Miller
Global Chief Communications Officer1.42yrsno datano data
Shigeto Ohtsuki
Corporate Officer & Human Resources Head0.67yrno datano data
Nobuhiro Abe
Managing Corporate Officer & Government Affairs Headno datano datano data
Ken Yoshimasu
Managing Corporate Officer & Head of Olympus Medical Technologies Asiano datano datano data

1.4yrs

Average Tenure

60yo

Average Age

Experienced Management: OCPN.F's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Yasuo Takeuchi
President1.42yrsno data0.0053%
¥ 1.4m
Stefan Kaufmann
Chief Administrative Officer1.25yrsno data0.000040%
¥ 10.4k
Sumitaka Fujita
Independent Chairman of the Boardno datano data0.00071%
¥ 184.5k
Nobuyuki Koga
Director1.25yrsno data0.0041%
¥ 1.1m
Tetsuo Iwamura
Independent Outside Director3.25yrsno data0.00023%
¥ 59.8k
Susumu Kaminaga
Independent Outside Director4.25yrsno data0.00016%
¥ 41.6k
Michijiro Kikawa
Independent Outside Director4.25yrsno datano data
Katsuya Natori
Independent Outside Director1.25yrsno data0.00071%
¥ 184.5k
Jimmy C. Beasley
Independent Outside Director1.25yrsno datano data
Yasumasa Masuda
Independent Outside Director2.25yrsno data0.00013%
¥ 33.8k
Atsushi Iwasaki
Independent Outside Director1.25yrsno data0.00065%
¥ 168.9k
David Hale
Independent Outside Director1.25yrsno datano data

1.3yrs

Average Tenure

63yo

Average Age

Experienced Board: OCPN.F's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Olympus Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Olympus Corporation
  • Ticker: OCPN.F
  • Exchange: OTCPK
  • Founded: 1919
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: JP¥2.729t
  • Listing Market Cap: JP¥25.989b
  • Shares outstanding: 1.29b
  • Website: https://www.olympus-global.com

Number of Employees


Location

  • Olympus Corporation
  • Shinjuku Monolith
  • 3-1 Nishi-Shinjuku 2-chome
  • Tokyo
  • 163-0914
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OCPN.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 1992
7733TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYJan 1992
OLY1DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1992
OCPN.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDSep 1995

Biography

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. The company operates through four segments: Medical Business, Scientific Solutions Business, Imaging Business, an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 05:43
End of Day Share Price2020/08/03 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.